Business Context and Reporting Period
This Form 8-K Current Report is filed by Conversion Labs, Inc. (not Lifemd, Inc.) with a report date of February 9, 2019. The filing discloses significant changes in executive leadership, specifically the resignation of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Resignation of CFO: Robert Kalkstein resigned as Chief Financial Officer, effective March 31, 2019. The resignation was not due to any disagreement regarding operations, policies, or practices.
- Appointment of New CFO: Juan Manuel Piñeiro Dagnery, previously the Company's Controller, was appointed as Chief Financial Officer, effective March 31, 2019.
- Compensation Adjustments:
- Mr. Kalkstein agreed to forego $32,500 of $42,500 in cash owed under his consulting agreement.
- Mr. Kalkstein's option exercise price was reduced from $0.40 to $0.28 per share for 500,000 options.
- 150,000 of Mr. Kalkstein's options were accelerated to vest on March 31, 2019, while 200,000 unvested options were cancelled.
Outlook, Risks, and Management Commentary
The new CFO, Mr. Piñeiro, entered into an employment agreement effective April 1, 2019, with the following terms:
- Salary: $84,000 per annum.
- Bonus: Eligible for an annual discretionary bonus of up to 100% of the base salary.
- Equity: Subject to Board approval, issuance of options to purchase 500,000 shares at an exercise price of $0.23.
- Termination: The agreement may be terminated without notice by either party at any time for any reason.
Mr. Kalkstein will continue to serve as an advisor to the Chief Executive Officer following his departure.
Investor Verification Checklist
- Verify the exact effective date of the CFO transition (March 31, 2019) and the interim period coverage.
- Review the filed Exhibits 10.1 and 10.2 for the complete legal terms of the Kalkstein Amendment and Piñeiro Employment Agreement.
- Confirm the Board's approval status regarding the issuance of 500,000 stock options to the new CFO.
- Assess the impact of the $32,500 cash forgiveness and option repricing on the company's immediate cash position and equity dilution.